Workflow for NHS Labs delivering SCID and SMA ISEs (ENLITE Methodology)

{
  "awards": [
    {
      "id": "020598-2026-1",
      "relatedLots": [
        "1"
      ],
      "status": "active",
      "suppliers": [
        {
          "id": "GB-FTS-176429",
          "name": "Birmingham Women\u0027s and Children\u0027s NHS Foundation Trust"
        }
      ]
    }
  ],
  "bids": {
    "statistics": [
      {
        "id": "3",
        "measure": "bids",
        "relatedLot": "1",
        "value": 1
      },
      {
        "currency": "GBP",
        "id": "1",
        "measure": "lowestValidBidValue",
        "relatedLot": "1",
        "value": 110028.1
      },
      {
        "currency": "GBP",
        "id": "2",
        "measure": "highestValidBidValue",
        "relatedLot": "1",
        "value": 110028.1
      }
    ]
  },
  "buyer": {
    "id": "GB-FTS-130973",
    "name": "NHS England"
  },
  "contracts": [
    {
      "awardID": "020598-2026-1",
      "dateSigned": "2026-03-05T00:00:00Z",
      "id": "020598-2026-1",
      "status": "active"
    }
  ],
  "date": "2026-03-06T16:25:24Z",
  "description": "This is a Provider Selection Regime (PSR) intention to award notice.\u003cbr/\u003e\u003cbr/\u003eThis intention to award notice is subject to Regulation 10 of the Health Care Services (Provider Selection Regime) Regulations 2023.\u003cbr/\u003e\u003cbr/\u003eFor the avoidance of doubt, this is not a procurement via PA23 or PCR 2015.\u003cbr/\u003e\u003cbr/\u003eThe standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by midnight on 17/03/2026.\u003cbr/\u003e\u003cbr/\u003eThis contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.\u003cbr/\u003e\u003cbr/\u003eWritten representations should be sent to england.commercialqueries@nhs.net, ensuring the following details are referenced:\u003cbr/\u003e\u003cbr/\u003eProject reference: C429690\u003cbr/\u003e\u003cbr/\u003eProject title: Workflow for NHS Labs delivering SCID and SMA ISEs (ENLITE Methodology) - Direct Award C process\u003cbr/\u003e\u003cbr/\u003eThis decision has been made as per NHS England governance processes, by the Commercial \u0026 Efficiency Control Approval on 5th March 2026. No conflicts of Interest were identified amongst decisionmakers.\u003cbr/\u003e\u003cbr/\u003eEach of the 5 key criteria were considered on the following basis and consideration was given to the basic selection criteria too.\u003cbr/\u003e\u003cbr/\u003eThe Authority evaluated providers against five mandatory key criteria:\u003cbr/\u003e\u003cbr/\u003eQuality and innovation 60%\u003cbr/\u003eValue 20%\u003cbr/\u003eIntegration, collaboration and service sustainability 10%\u003cbr/\u003eImproving access and reducing inequalities and facilitating choice 5%\u003cbr/\u003eSocial value 5%.\u003cbr/\u003e\u003cbr/\u003eFollowing provider assessments, it was agreed that the Birmingham Women\u0027s and Children\u0027s Foundation Trust were the only providers capable of meeting the service specifications and requirements of the NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) contracts, with the addition of the ISE for Spinal Muscular Atrophy (SMA) in full.",
  "id": "020598-2026",
  "initiationType": "tender",
  "language": "en",
  "ocid": "ocds-h6vhtk-0664a3",
  "parties": [
    {
      "address": {
        "countryName": "United Kingdom",
        "locality": "London",
        "postalCode": "SE1 8UG",
        "region": "UKJ1",
        "streetAddress": "Wellington House, 133-135 Waterloo Rd"
      },
      "contactPoint": {
        "email": "england.commercialqueries@nhs.net",
        "name": "NHS England"
      },
      "details": {
        "buyerProfile": "https://www.england.nhs.uk/",
        "classifications": [
          {
            "description": "Body governed by public law",
            "id": "BODY_PUBLIC",
            "scheme": "TED_CA_TYPE"
          },
          {
            "description": "Health",
            "id": "07",
            "scheme": "COFOG"
          }
        ],
        "url": "https://www.england.nhs.uk/"
      },
      "id": "GB-FTS-130973",
      "identifier": {
        "legalName": "NHS England"
      },
      "name": "NHS England",
      "roles": [
        "buyer"
      ]
    },
    {
      "address": {
        "countryName": "United Kingdom",
        "locality": "Birmingham",
        "postalCode": "B15 2TG",
        "region": "UK",
        "streetAddress": "C/O Birmingham Women\u0027s Hospital  Mindelsohn Way"
      },
      "contactPoint": {
        "email": "martyngreen@snsg.co.uk"
      },
      "details": {
        "scale": "sme",
        "url": "http://www.bch.org.uk"
      },
      "id": "GB-FTS-176429",
      "identifier": {
        "id": "10841099",
        "legalName": "Birmingham Women\u0027s and Children\u0027s NHS Foundation Trust"
      },
      "name": "Birmingham Women\u0027s and Children\u0027s NHS Foundation Trust",
      "roles": [
        "supplier"
      ]
    },
    {
      "address": {
        "countryName": "United Kingdom",
        "locality": "London,",
        "postalCode": "WC2A 2LL",
        "streetAddress": "Strand,"
      },
      "details": {
        "url": "https://www.theroyalcourtsofjustice.com"
      },
      "id": "GB-FTS-87082",
      "identifier": {
        "legalName": "High Court"
      },
      "name": "High Court",
      "roles": [
        "reviewBody",
        "mediationBody",
        "reviewContactPoint"
      ]
    }
  ],
  "tag": [
    "award",
    "contract"
  ],
  "tender": {
    "classification": {
      "description": "Services provided by medical laboratories",
      "id": "85145000",
      "scheme": "CPV"
    },
    "description": "This is a Provider Selection Regime (PSR) Intention-to-Award Notice.\u003cbr/\u003e\u003cbr/\u003eThis notice is subject to Regulation 10 of the Health Care Services (Provider Selection Regime) Regulations 2023.\u003cbr/\u003e\u003cbr/\u003eFor the avoidance of doubt, this is not a procurement via PA23 or PCR 2015.\u003cbr/\u003e\u003cbr/\u003eThis is a notice of intention to make an award to one provider in respect of the Service pursuant to the Direct Award C process via PSR for the services of ENLITE Methodology Screening Labs, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID), with the addition of the ISE for Spinal Muscular Atrophy (SMA), as recommended by the UK NSC.\u003cbr/\u003e\u003cbr/\u003eThis is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.\u003cbr/\u003e\u003cbr/\u003ePursuant to the NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) contracts, with the addition of the ISE for Spinal Muscular Atrophy (SMA), the providers are to provide the following functions:\u003cbr/\u003e\u003cbr/\u003e\u2022 Specialist scientific and clinical workforce required to deliver assurance, quality oversight, and programme reporting.\u003cbr/\u003e\u2022 Laboratory capacity and turnaround requirements to support in\u2011service evaluation activity alongside existing SCID delivery.\u003cbr/\u003e\u2022 Quality assurance and quality control processes, including maintenance of consistent methodologies, validation status, and reporting standards.\u003cbr/\u003e\u2022 Information governance, data management, and secure data flows required to support national screening evaluation and reporting.\u003cbr/\u003e\u2022 Programme management and coordination activity necessary to support continuity and comparability of in\u2011service evaluation outputs.",
    "id": "C429690",
    "items": [
      {
        "deliveryAddresses": [
          {
            "region": "UK"
          }
        ],
        "id": "1",
        "relatedLot": "1"
      }
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "lots": [
      {
        "awardCriteria": {
          "criteria": [
            {
              "description": "80",
              "name": "Direct Award C criteria",
              "type": "quality"
            },
            {
              "description": "20",
              "name": "Value",
              "type": "cost"
            }
          ]
        },
        "description": "Pursuant to the NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) contracts, with the addition of the ISE for Spinal Muscular Atrophy (SMA), the providers are to provide the following functions:\u003cbr/\u003e\u003cbr/\u003e\u2022 Specialist scientific and clinical workforce required to deliver assurance, quality oversight, and programme reporting.\u003cbr/\u003e\u2022 Laboratory capacity and turnaround requirements to support in\u2011service evaluation activity alongside existing SCID delivery.\u003cbr/\u003e\u2022 Quality assurance and quality control processes, including maintenance of consistent methodologies, validation status, and reporting standards.\u003cbr/\u003e\u2022 Information governance, data management, and secure data flows required to support national screening evaluation and reporting.\u003cbr/\u003e\u2022 Programme management and coordination activity necessary to support continuity and comparability of in\u2011service evaluation outputs.\u003cbr/\u003e\u003cbr/\u003eThe Commissioner intends to award a contract following the Direct Award C process to the existing provider. This is an expansion of existing services which, under PSR, constitutes a new service.\u003cbr/\u003e\u003cbr/\u003eThe services will start on 1st April 2026 and the initial period will run until 31st March 2028 with an option to extend for up to a further 1 year.\u003cbr/\u003e\u003cbr/\u003eThis procurement exercise will utilise the Most Suitable Provider (MSP) award process via the NHS Provider Selection Regime (PSR) regulations.\u003cbr/\u003e\u003cbr/\u003eThe sourcing decision was taken in line with the Provider Selection Regime. The Basic Criteria were assessed and confirmed as met. A Most Suitable Provider approach was applied to secure continuity of specialist in service evaluation activity using established providers and methodologies\u003cbr/\u003e\u003cbr/\u003eThe Authority evaluated providers against five mandatory key criteria:\u003cbr/\u003e\u003cbr/\u003eQuality and innovation 60%\u003cbr/\u003eValue 20%\u003cbr/\u003eIntegration, collaboration and service sustainability 10%\u003cbr/\u003eImproving access and reducing inequalities and facilitating choice 5%\u003cbr/\u003eSocial value 5%.\u003cbr/\u003e\u003cbr/\u003eExisting break and exit clauses are retained and relied upon in the general conditions to manage risk and affordability. These provisions provide NHS England with the ability to vary or exit the arrangement should the national screening policy, service configuration, or delivery models change, thereby mitigating the financial risk associated with the increased contract value.\u003cbr/\u003e\u003cbr/\u003eThe standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by midnight on Wednesday, 18 March 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR. Written representations should be sent to england.commercialqueries@nhs.net, ensuring the following details are referenced:\u003cbr/\u003e\u003cbr/\u003eProject reference: C429690\u003cbr/\u003eProject title: Workflow for NHS Labs delivering SCID and SMA ISEs (ENLITE Methodology)",
        "hasOptions": false,
        "id": "1",
        "status": "cancelled"
      }
    ],
    "mainProcurementCategory": "services",
    "procurementMethod": "limited",
    "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
    "procurementMethodRationale": "The procurement falls outside the scope of application of the regulations.\u003cbr/\u003e\u003cbr/\u003eExplanation:\u003cbr/\u003e\u003cbr/\u003eThis is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023.\u003cbr/\u003e\u003cbr/\u003eFor the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice.\u003cbr/\u003e\u003cbr/\u003eRepresentations by providers must be made to decision makers by Tuesday 17th March 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.",
    "procurementMethodRationaleClassifications": [
      {
        "description": "The procurement falls outside the scope of application of the directive",
        "id": "D_OUTSIDE_SCOPE",
        "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL"
      }
    ],
    "status": "complete",
    "title": "Workflow for NHS Labs delivering SCID and SMA ISEs (ENLITE Methodology)"
  }
}